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MANAGEMENT OF RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER 
IN PATIENTS WITH PARKINSON’S DISEASE 
MICHAEL CAMERON JEFFRIES 
ABSTRACT 
 Among all of the devastating effects that Parkinson’s disease (PD) has on an 
individual, sleep dysfunction is one that can have a profound effect on the entire family 
of the patient. The most potentially destructive of these sleep syndromes being that of 
Rapid Eye Movement Sleep Behavior Disorder (RBD). This disorder not only causes 
sleep impairment to the patient, but can occasionally result in life-threatening injury to 
the individual or their bed partner.  
 While this condition is manageable with medication, the current treatment of 
choice is a long-acting benzodiazepine, clonazepam. This drug, while effective in treating 
RBD, comes with a significant burden of side effects. Patients with neurodegenerative 
disorders, like PD, are at even higher risk of suffering the negative impacts of this 
treatment.  
 One potential alternative treatment that has been considered is a supplement of 
exogenous melatonin, a hormone that plays a role in maintaining one’s circadian rhythm. 
Several small case studies have shown potential efficacy of this treatment, and with very 
few side effects. However, this efficacy has not yet been proven by randomized clinical 
trial.  
 This proposed study will perform a double-blind randomized clinical trial of 
melatonin vs. placebo in a population of PD patients with RBD. Subjects will be analyzed 
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via polysomnographic sleep study, where symptoms will be scored on the RBD Severity 
Scale (RBDSS) at baseline and after a treatment intervention. Statistical analysis will 
then ascertain whether or not a significant symptom reduction is seen following 
melatonin treatment, compared to a group receiving placebo.  
 If melatonin proves to be efficacious in this patient population, this would give 
clinicians a new treatment option to consider to effectively manage symptoms of RBD 
with a much lower risk of potentially harmful side effects. Finding an effective method of 
managing this condition, the prevalence of which continues to rise worldwide, will have a 
great impact on improving the safety and quality of life of these patients.  
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INTRODUCTION 
Background 
Rapid Eye Movement Sleep Behavior Disorder (RBD) is clinically defined by a loss of 
one’s skeletal muscle atonia that normally occurs during the rapid eye movement (REM) 
phase of sleep. This disorder is associated with motor activity during REM sleep, as well 
as dream enacting behaviors. These movements can range from benign muscle twitching 
to aggressive, potentially violent movements which can frequently pose a risk of harm to 
both the individual and their bed partner. It is estimated that approximately one-third of 
Parkinson’s disease patients will experience RBD symptoms during or prior to the onset 
of the neurodegenerative symptoms of PD.1 The disorder has a tendency to affect 
individuals over the age of 50, and has a male predominance.2  
 
Statement of the Problem 
Currently, the standard of care for patients suffering from this condition is treatment with 
clonazepam, a benzodiazepine. This treatment carries its own significant risks and side 
effects, including tolerance and dependence. In patients suffering from the 
neurodegenerative pathology of Parkinson’s disease, treatment with a benzodiazepine can 
lead to lingering sedative effects during daytime hours, as well as further loss of physical 
coordination leading to falls and injury.2 In elderly patients, clonazepam also has been 
shown to lead to higher incidence of obstructive sleep apnea and decline in cognitive 
function.1  Melatonin on the other hand seems to carry much fewer side effects, and 
seems to have very little risk of dependence. In small case studies, melatonin 
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supplements have shown to be successful in decreasing the symptoms of RBD.1,3,4 
However, to this point, no randomized clinical trials have directly analyzed the efficacy 
of melatonin in managing symptoms of RBD, which is necessary to determine whether 
melatonin could be effective for pharmacologic management of RBD in Parkinson’s 
disease patients.5  
 
Hypothesis 
The addition of a melatonin supplement at bedtime will decrease symptoms of REM 
Sleep Behavior Disorder in patients with Parkinson’s disease with greater efficacy than a 
placebo.  
 
Objectives and specific aims 
In conducting this research, the overall goal is that a safer, more efficacious therapy for 
treating RBD symptoms can be recommended. If the hypothesis of this study holds true, 
ideally a new first-line treatment of melatonin can be recommended for Parkinson’s 
patients with RBD, which will decrease the likelihood of injury to the patient and their 
bed partner during sleep, but also have a low side effect profile to ensure that the patient 
remains safe and fully functional during wakeful hours. Specific aims of this study will 
include:  
• Determine whether treatment with melatonin will bring about a greater decrease 
in the symptoms of RBD compared to a placebo. 
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• Study the aforementioned objective in a population of patients with Parkinson’s 
disease, who are at increased risk for RBD, and at increased risk for negative side 
effects from treatment with benzodiazepines.  
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REVIEW OF THE LITERATURE 
Overview 
Parkinson’s disease 
The disease that is currently known as Parkinson’s disease was first described by 
John Parkinson in 1819. Initially named “Shaking Palsy” or “Paralysis agitans”, 
Parkinson described the characteristics of the disease as “Involuntary tremulous motion, 
with lessened muscular power, in parts not in action and even when supported; with a 
propensity to bend the trunk forwards, and to pass from a walking to a running pace: the 
senses and intellects being un-injured”.6 
From this initial description of the disease nearly two hundred years ago, much 
has changed in terms of our knowledge and understanding of the disease process, yet the 
fundamental clinical diagnosis is still based off the cardinal symptoms that he describes; 
that of tremor, bradykinesia, rigidity, and postural instability.7 However, it is now 
understood that these four cardinal symptoms are associated with a broad range of 
neurodegenerative disorders, and therefore this clinical presentation is more properly 
classified as parkinsonism syndrome.8 When a patient is found to possess the diagnostic 
criteria for parkinsonism, the differential diagnosis certainly includes Parkinson’s 
disease, but also Essential tremor, Vascular parkinsonism, Dementia with Lewy bodies, 
Progressive supranuclear palsy, Multisystem atrophy, Corticobasal degeneration, and 
many other secondary forms of parkinsonism. Distinguishing these conditions from one 
another can be very difficult for a clinician, especially in the early stages of disease; yet 
diagnostic accuracy is incredibly important for proper therapeutic intervention. Error 
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rates in diagnosing Parkinson’s disease, even by movement disorder specialists, has been 
shown to be as high as 24%.8 
It has been estimated that Parkinson’s disease currently affects about 1 million 
individuals in the United States. The disease has an affinity toward the male gender, and 
increases in prevalence with advanced age, rarely affecting those under age 40. 
Approximately 1% of the population of individuals over age 60 are estimated to be 
afflicted with the disease, which is steadily increasing as the population ages. It has not 
been shown that there is any increased likelihood of PD among specific races or ethnic 
groups.9 The worldwide prevalence of this disease is expected to double from 2005 to 
2030; although this may be a testament to the fact that individuals receiving treatment are 
living longer with the disease.10 
The pathogenesis of PD is a constantly evolving picture which has undergone 
decades of intense study. To this day, the etiology of this condition is thought to be multi-
factorial, including several potential genetic predisposing factors. Family history may 
play a role, where approximately 10-15% of affected individuals report a positive family 
history of a similar disorder.11 To this date, approximately 10 gene loci have been found 
to have an association with PD, however, no single gene mutation has been found to lead 
to the disease.  
In the late 1950’s, it was discovered that there was a link between dopamine 
deficiency and the development of PD. More recent studies of the brains of PD patients 
using positron emission tomography have shown that there is a decrease in neuronal 
uptake of radiolabeled 18F-fluorodopa in the striata. This suggests that impaired 
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neurotransmission of dopamine may be the contributing factor to the pathogenesis of 
PD.12 It has been found that patients with PD undergo a selective loss of neurons within 
the substantia nigra pars compacta, which project to the striata and are responsible for the 
release of dopamine. This is the initial step in the signaling pathway leading to the motor 
cortex. It is estimated that when at least 50% of these neurons have been lost, 
parkinsonian features begin to arise.11  Additionally, in the early 1900’s Friedrich 
Heinrich Lewy found that when microscopically examining the neurons of PD patients, 
they were noted to have proteinaceous cytoplasmic inclusion bodies. Now known as 
Lewy bodies, these aggregations of alpha-synuclein protein are considered one of the 
common pathologic factors associated with PD as well as several other 
neurodegenerative conditions. It remains unknown whether this phenomenon is a 
causative factor of the disease, or simply a result of other pathologic factors.12 
The symptoms associated with PD can be broken down into two categories, motor 
and non-motor symptoms. The motor symptoms are the most characteristic of the disease, 
and include those previously mentioned: tremor, bradykinesia, rigidity, and postural 
instability.9 The non-motor symptoms, while not as specific to PD, can be equally 
detrimental to patient’s quality of life, and occasionally can even be life threatening. 
These symptoms broadly include neuropsychiatric symptoms, sleep disorders, autonomic 
dysfunction, gastrointestinal symptoms, sensory symptoms, and many others.13 
Of the motor symptoms of PD, the most pathognomonic association of the disease 
is that of a resting tremor. The resting tremor of PD is typically noted to develop 
asymmetrically in a single limb, most often a hand. Tremulousness of the affected limb 
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only occurs when voluntary motion is not taking place; once the individual initiates 
movement of the limb the tremor will cease. This differentiates the tremor of PD from 
that of Essential tremor, in which tremulousness will be brought on when the individual 
is performing voluntary movement of the affected limb. Classically, walking tends to 
bring about the resting tremor of PD. The tremor can also affect the chin, jaw, and 
tongue, but rarely causes a tremor of the entire head. Tremor can also be absent in 
approximately 20% of individuals with PD.9  
Similar to the resting tremor, bradykinesia associated with PD also tends to occur 
asymmetrically. This symptom is most typically reported by patients as a unilateral 
weakness of a either a hand or leg, however, no strength deficits are usually noted on 
physical exam. However, when assessing a PD patient’s repetitive movement ability via 
finger tapping or toe tapping, the examiner may notice that the patient’s movement will 
decrease in speed, amplitude of motion may be reduced, and cadence of rhythm may 
become irregular over time while performing this exercise. This can manifest for the 
patient at home as a difficulty with repetitive motions such as brushing ones teeth. The 
patient may also report difficulties at home with activities that require fine motor 
coordination, such as buttoning a shirt, or writing.9 There also tends to be slowness in 
both initiating and carrying out movements, and loss of some spontaneous movement 
altogether.14 
The rigidity of PD is often described by the patient as “stiffness associated with 
vague aching and discomfort of a limb”.9 These vague symptoms often lead to 
misdiagnosis as a simple musculoskeletal injury. This rigidity can eventually lead to 
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complete immobilization of a joint, such as frozen shoulder, but this is more typical in 
advanced disease.9 
Postural instability is another frequent manifestation of PD, which tends to arise 
with more advanced disease. Most commonly noted is a “simian posture” or an increased 
kyphosis of the thoracic spine. There can also be lateral bending of the trunk, flexion of 
the forearms, ulnar deviation of the digits, and inversion with plantar flexion of the feet.14 
The combination of these cardinal symptoms of PD tend to lead to other 
characteristic findings in these patients. Gait disturbance is common, with the classic 
finding of the “shuffling gait” with dragging of one or both feet and decreased arm swing, 
as well as a narrow separation of the feet. Transitioning from sitting to standing position 
tends to be difficult for these patients. Handwriting alteration is another common 
characteristic of PD patients, where one’s handwriting tends to become noticeably 
smaller with irregularities in letter sizing and spacing.9 Speech can become altered as 
well, with monotony and low volume commonly observed, and occasionally notable 
dysarthria.14 
While the motor symptoms of PD are the most characteristic of the disease, the 
non-motor symptoms tend to be equally detrimental to the quality of life of these patients. 
The non-motor symptoms originate from a similar pathophysiologic mechanism as the 
motor symptoms, resulting from the deterioration of dopaminergic neurons within certain 
key areas of the brain. Often the non-motor symptoms will precede the motor symptoms, 
and currently research is being pursued to utilize these early onset symptoms to make an 
earlier diagnosis of PD. Braak and colleagues have designed a staging system that 
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correlates the non-motor and motor symptoms of PD to a patient’s likely stage of disease 
based upon their level of neurodegeneration. Braak stage 1 is associated with 
degeneration of the olfactory bulb and will lead to olfactory dysfunction in the patient. 
Braak stage 2 is associated with early changes to the lower brainstem and is characterized 
by sleep dysfunction, including REM sleep behavior disorder, and autonomic instability. 
Braak stage 3 and 4 signify the beginnings of the motor symptoms of PD where the 
classic tremor, bradykinesia, and rigidity begin to appear, and also when PD is formally 
diagnosed. These stages are associated with the loss of neurons within the substantia 
nigra. Braak stages 5 and 6 are associated with the development of Lewy bodies and the 
development of cognitive deficits, psychiatric symptoms, and visual hallucinations. Many 
of the non-motor symptoms, however, do not neatly fit into one of the aforementioned 
Braak stages, and can seemingly affect patients at any stage of the disease.13  
One of the earliest, more prominent symptoms that occurs in PD is that of sleep 
dysfunction. Nearly all patients with PD have been shown to have some form of sleep 
dysfunction. While the cause of this dysfunction is multifactorial, it is thought that 
degeneration of the brainstem and thalamocortical pathways involved in sleep regulation 
are responsible for these symptoms. Sleep disturbances can vary from insomnia, to 
disruption of normal circadian rhythm cycles, to loss of normal muscle atonia during 
REM sleep, known as REM sleep behavior disorder. Alterations in normal sleep 
architecture can lead to issues such as decreased sleep latency similar to narcolepsy, 
disordered breathing or sleep apnea, nocturia, and poor quality sleep overall. Up to 50% 
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of PD patients report excessive daytime sleepiness and falling asleep throughout the 
day.13  
Neuropsychiatric disorders are another common non-motor symptom of PD. Most 
typical among these are mood disorders. Depression is one of the most typical to be seen 
in early stages of PD, the cause of which seems to be a combination of pathological PD 
changes and simply reaction to diagnosis of a neurodegenerative disease. However 
studies have also shown that a history of depression may be a risk factor for PD in itself, 
where one study showed that patients with a clinical history of depression were 13.3 
times more likely to develop PD than a control group.15 Anxiety and apathy are also 
common psychiatric symptoms facing PD patients, however, this is more commonly a 
side effect of anti-parkinsonian drug therapy rather than part of the disease course.13 
Frank psychosis and visual hallucinations can occur with PD as well, but this is more 
typically seen in advanced stage disease due to the development of Lewy bodies in the 
temporal/limbic cortex. However, psychosis can also be a result of antiparkinsonian 
therapy with dopamine agonists, levodopa, amantadine, and anticholinergics.15 
Cognitive impairment is associated more typically with end-stage disease, and has 
an incidence in PD that is four times greater than the general population. The 
pathophysiology leading to dementia and cognitive deficits is typically the propagation of 
Lewy bodies within the cortex of the brain, which occurs in advanced disease. Age is the 
primary risk factor for development of dementia in PD, but also included are male 
gender, poor socioeconomic status, and increase severity of motor symptoms. The most 
common cognitive deficits noted in PD patients are attention, executive function, and 
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visuospatial awareness. Decreased cognitive function is associated with a worse quality 
of life, worsened prognosis, and greater likelihood that the patient will require placement 
in a long term care facility.15 
Autonomic dysfunction is a manifestation that can occur frequently in PD, 
although the pathophysiology is quite complex and not fully understood. Underlying 
these symptoms is the neurodegeneration of various nuclei responsible for control of 
sympathetic preganglionic neurons in the descending pathways; as well as impaired 
function of cholinergic, monoaminergic, and serotonergic nuclei. Most common 
symptoms reported in PD patients include orthostatic hypotension, constipation, bladder 
dysfunction, erectile dysfunction, and hyperhidrosis. Autonomic dysfunction is typically 
a manifestation of more advanced stage PD.13 
Many tools have been developed and utilized to determine the stage and severity 
of disease in PD, however, the scale developed by Hoehn and Yahr in 1967 remains one 
of the most widely used clinical measures to report the patient’s degree of disability.14 In 
2004, the Movement Disorder Society Task Force adapted a Modified Hoehn and Yahr 
Scale with additional increments, allowing for more specific staging of Parkinson’s 
disease progression and disability, which is now more commonly utilized.16 
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Table 1. Modified Hoehn and Yahr Scale. (Used to rate the progression of disease 
and degree of disability of PD patients)16  
 
“Stage 
1.0 
Unilateral involvement only 
Stage 1.5 Unilateral and axial involvement 
Stage 2.0 Bilateral involvement without impairment of balance 
Stage 2.5 Mild bilateral disease with recovery on pull test 
Stage 3.0 Mild to moderate bilateral disease; some postural instability; physically 
independent  
Stage 4.0 Severe disability; still able to walk or stand unassisted 
Stage 5.0 Wheelchair bound or bedridden unless aided”16 
 
As the pathology of PD directly relates to the loss of dopamine neurotransmission 
to the striatum, it was proposed nearly 50 years ago that intake of an exogenous 
dopamine supplement or dopaminergic agonist could potentially reverse the effects of the 
disease. Dopamine itself was found to be unable to cross the blood brain barrier, making 
it an ineffective drug. Thus levodopa, an amino acid compound which acts as an 
intermediate in the dopamine synthesis pathway, was found to successfully cross the 
blood brain barrier and then undergo conversion to dopamine.11 The ELLDOPA (Earlier 
versus Later Levodopa Therapy in Parkinson’s disease) study found Levodopa to have a 
dose-dependent improvement in parkinsonian symptoms over a 40 week treatment period 
compared to placebo. This study also showed Levodopa to have many neuroprotective 
benefits, showing a lesser degree of disease progression and neurodegeneration compared 
to those receiving placebo.17  
Levodopa therapy does not come without side effects however, where nearly one 
half of patients within five years of initiating treatment were shown to have a classic side 
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effect profile of motor fluctuations and dyskinesia. Younger patients seem especially 
susceptible to these effects. It has been found however, that Levodopa treatment with the 
addition of a dopamine agonist may decrease the risk of such side effects. Also 
postponing the initiation of Levodopa treatment or utilizing a different treatment option 
during mild to moderate stages of disease may prove beneficial in lowering risk of motor 
side effects.11  
Levodopa therapy can lead to peripheral dopaminergic side effects as well, 
including hypotension and nausea. To avoid these effects, the drug is now typically 
prescribed in combination with a peripheral acting aromatic L-amino acid decarboxylase 
(AAAD) inhibitor, also known as carbidopa. In addition, Levodopa/carbidopa (Sinemet) 
is often prescribed with a catechol O-methyltransferase (COMT) inhibitor, also called 
entacapone. This prevents O-methlyation of Levodopa and prolongs its effects.9  
Other second line treatment options for the motor symptoms of PD include 
anticholinergics, selective MAO-B inhibitors, and NMDA antagonists (amantadine). 
Anticholinergics are very rarely used due to their poor side effects, but can be helpful in 
patients in whom tremor remains a life-altering symptom and is not controlled by other 
medications. MAO-B inhibitors and amantadine have few side effects and have relatively 
simple dosage titration, however, these drugs alone are not particularly efficacious at 
treating motor symptoms of PD. Some research suggests however that MAO-B 
inhibitors, among other drugs, may have some neuroprotective benefits and may slow 
progression of disease.9 
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For severe motor symptoms that remain refractory to medications, surgical 
intervention can be highly efficacious. The typical surgical approach is known as deep 
brain stimulation with implantable electrodes placed into the thalamus via thalamotomy. 
Pallidal stimulation and sub-thalamic stimulation are occasionally utilized as well.9 The 
FDA has approved deep-brain stimulation for patients “as an adjunctive therapy in 
reducing some of the symptoms of advanced, levodopa-responsive Parkinson’s disease 
that are not adequately controlled by medication.”18 This intervention is only performed 
in patients who have failed several attempts at controlling symptoms with various 
medication combinations, patients who are severely impaired in gait, balance, and 
speech, and patients in whom dyskinesias and other medication related side effects are an 
issue. Deep brain stimulation works by altering the pattern of neuron activity in the basal 
ganglia, increasing local neurotransmitter release, and increasing blood flow to promote 
neurogenesis. However, it remains largely unknown as to how this treatment specifically 
alters the symptoms of PD.18 
 
REM Sleep Behavior Disorder 
 REM Sleep Behavior Disorder (RBD) is a parasomnia which was first described 
by Schenck et al in 1986.19 The condition is described as a loss of the normal muscle 
atonia that occurs during the REM phase of sleep. Patients with this disorder tend to 
exhibit motor activity during sleep, typically in association with dreaming. This activity 
can be as subtle as a minor twitch, or be violent and aggressive, potentially causing harm 
to themselves or their bed partner. More severe behaviors associated with RBD can be 
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quite complex, including hitting, grabbing, trying to defend oneself, leaping out of bed, 
and occasionally walking. Some patients vocalize during sleep, either as incoherent 
mumbling or sometimes as fluent speech. Typically these behaviors are associated with 
vivid, typically unpleasant dreaming. In one study of 58 patients, it was found that 91% 
of patients who showed motor behaviors during sleep were found to have had dreams 
where they were in danger, either fighting or fleeing.20  
RBD has been found to have a male predominance, and tends to affect those in 
the age range from 40-70.21 A great deal of research has been compiled showing an 
association of RBD development in patients with neurodegenerative disorders, especially 
alpha-synucleinopathies. RBD has been shown to affect nearly 60% of patients with PD, 
and 80-100% of patients with Lewy body dementia (DLB) and multiple system atrophy 
(MSA).20 Interestingly, the onset of RBD tends to precede the more notable symptoms of 
these neurodegenerative disorders by years or even decades, so researchers are currently 
looking for a way to predict the onset of such disorders based on the onset of RBD 
symptoms.21   
To make a clinical diagnosis of RBD, a clinician must note the following criteria 
in the patient, from the 2005 edition of the International Classification of Sleep 
Disorders:  
i. “Presence of REM sleep without atonia (RWSA) on 
polysomnography (PSG) 
ii. At least one of the following: 
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a. Sleep-related, injurious, potentially injurious or disruptive 
behaviours by history (i.e. dream enactment behaviour) and/or 
b. Abnormal REM sleep behavior documented during 
polysomnographic monitoring. 
iii. Absence of EEG epileptiform activity during REM sleep unless 
RBD can be clearly distinguished from any concurrent REM sleep-
related seizure disorder. 
iv. The sleep disorder is not better explained by another sleep 
disorder, medical or neurological disorder, mental disorder, 
medication use of substance use disorder.”22 
 
The pathophysiology behind RBD is quite complex, and a great deal remains to 
be uncovered. In patients with RBD, spinal interneurons are stimulated during REM sleep 
and have an excitatory effect on muscle fibers. These spinal interneurons receive 
excitatory stimulation from locomotor generators, and inhibitory stimulation by a 
complex network of nuclei, whose net effect in non-RBD individuals is overall inhibition 
of spinal interneurons leading muscle atonia during REM sleep. In patients with RBD, 
there is a defect of the sublaterodorsal nucleus in its ability to stimulate the inhibitory 
effects onto the spinal interneurons, thus allowing excitation of skeletal muscle fibers.23  
As RBD symptoms can be incredibly dangerous and at times life-threatening, it is 
incredibly important that this condition be effectively addressed and treated. Currently, 
the first-line drug therapy for RBD is clonazepam, a benzodiazepine. This medication 
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however, comes with somewhat dangerous risks and side effects, including tolerance and 
dependence, daytime sleepiness, impairments in cognition, and worsening physical 
coordination. It can cause progression of pre-existing sleep disorders as well, such as 
obstructive sleep apnea. In elderly patients, and especially patients with 
neurodegenerative disorders, these side effects can be incredibly harmful, and impair 
their already deteriorating quality of life.24  
Some studies have looked at the use of a melatonin supplement to be used as 
treatment for RBD. Melatonin has a much lower side effect profile, and seems to be just 
as efficacious as clonazepam in decreasing the symptoms of RBD. Additionally, 
melatonin can be beneficial in correcting the circadian rhythm of these patients, whose 
sleep cycles tend to have some degree of impairment.25 
 
Existing research 
 For a clinician to choose a medication to properly manage the symptoms of RBD 
in patients, they must take into consideration both the efficacy of the treatment, and the 
side effect profile of the drug. Especially in patients with PD, who are typically advanced 
in age, and have neurodegenerative disease, finding a treatment that will not cause the 
patient additional harm is extremely important. The standard of care currently is that of 
clonazepam. This was initially determined to be the gold standard treatment by Schenck 
et al, who initially discovered this disease.19 While clonazepam has been shown to be 
effective in many patients for symptom management, the side effects that this drug poses 
to patients are quite significant. 
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 Clonazepam is a long-acting benzodiazepine with sedative properties, and has a 
half-life of between 20 and 50 hours. Its mechanism of action in treating RBD is not fully 
understood, but it has been shown that the drug successfully “reduces phasic EMG 
activity but does not restore tonic REM sleep muscle inactivity”.24 In a retrospective 
analysis performed by Anderson et al, 54% of patients prescribed clonazepam for 
treatment of their RBD symptoms reported an overall benefit from the medication. 
Within this same group however, 58% reported moderate or severe side effects as a result 
of the drug. Most of these patients requested to either stop the medication, switch to an 
alternative treatment, or decrease the dose, despite seeing relief in their sleep symptoms. 
The most common reported side effects from this study were lingering daytime 
sleepiness, confusion, and cognitive impairment. These authors concluded that, while 
clonazepam seems to be an effective treatment for RBD, the side effects that result from 
its use lead it to be an unsatisfactory therapy for this condition.24 
 While several other drugs are being researched as potential treatments for this 
disorder, one that seems to show promising results in terms of efficacy and low risk of 
side effects is exogenous melatonin. Melatonin is a hormone that seems to play a role in 
the maintenance of circadian rhythm in humans. Secretion of melatonin has been shown 
to be highest in the late evening, and lowest in the morning; and seems to be inversely 
related to times of peak sunlight exposure. The area of the brain with greatest receptor 
density for melatonin is the suprachiasmatic nucleus (SCN), which seems to be the region 
that drives circadian rhythm synchronization in mammals. Exogenous melatonin 
supplementation has shown several benefits in humans to date, including recovery from 
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jet lag, facilitating earlier phase sleep in patients with sleep phase-delay syndromes or 
shift work disorders, and restoring a proper day-night sleep cycle in blind individuals. 
The overall effect of exogenous melatonin seems to be that of restoring or shifting ones 
circadian rhythm. Recent data from SCN lesion studies have shown that circadian 
rhythms and REM sleep continuity are impaired by lesions to the SCN; which could play 
a role in the pathophysiology of RBD. Kunz and Bes hypothesized that among other 
things, one of the primary driving factors in the development of RBD is circadian rhythm 
desynchronization, which exogenous melatonin could help to restore.26  
 To date, several studies have been performed that have shown a significant 
improvement in RBD symptoms with melatonin treatment. The first study to examine 
this therapy was performed by Kunz and Bes in 1999 in a study of six patients with RBD 
who were given open-label melatonin treatment, and followed with polysomnographic 
studies, actigraphy, and sleep diaries. The study results showed significant clinical 
improvement in patient’s RBD symptoms, with polysomnographic improvement in REM 
sleep parameters and a decrease in motor activity during sleep with melatonin 
supplement.26  
In 2001, Takeuchi et al. reconfirmed these findings in a study of 15 patients which 
analyzed similar parameters, and additionally analyzing patient’s baseline melatonin 
secretion. This study again showed a significant suppression of RBD associated sleep 
behaviors, especially in patients with low baseline melatonin secretion.4 
In 2003, a study by Boeve et al. similarly assessed the outcomes of RBD 
symptoms with melatonin therapy, but specifically looked at patients with concurrent 
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neurodegenerative disorders. The decision to study this population of patients was 
decided based on the fact that these are the patients who tend to be at increased risk of 
developing RBD, but also because these patients are at greater risk of negative side 
effects from treatment with clonazepam. This study showed a persistent benefit with 
melatonin in 57% of patients with very few reported side effects.3 
While melatonin seemed to show very positive results in treating RBD symptoms 
in these preliminary studies, it remained to be shown how this therapy compared to the 
first-line treatment, clonazepam. In 2013, McCarter et al. performed a retrospective 
analysis of RBD patients treated at Mayo Clinic from 2008-2010 comparing those treated 
with clonazepam to those treated with melatonin. The findings of this study showed that 
melatonin and clonazepam showed similar results in terms of treatment efficacy, 
however, the side effects associated with clonazepam were far greater than those treated 
with melatonin. Interestingly however, in a subgroup analysis of patients with 
neurodegenerative disorders, melatonin-treated patients showed a statistically significant 
reduction in RBD symptom ratings, while clonazepam-treated patients showed a 
reduction that was not statistically significant. This study also determined a median 
effective dose of both melatonin and clonazepam, 6mg and 0.5mg respectively.25 
While many studies simply analyze RBD symptoms based on subjective data 
from patient and family member reports of symptoms, a more objective measurement of 
RBD symptoms would provide for a more accurate study of treatment efficacy. In 2011, 
Sixel-Döring et al. devised an effective scale to quantify severity of symptoms in RBD 
patients. This RBD severity scale (RBDSS) is based on polysomnographic analysis of 
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patients, and specifically rates patients based on motor symptoms and nighttime 
vocalizations. Motor symptoms are based on a 0-3 scale, where 0 = no movement, 1 = 
slight movements or jerks, 2 = movements involving the proximal extremities, and 3 = 
axial movement or bed falls. Vocalizations are scored either 0 or 1, based on their 
absence or presence respectively.27 This scale was slightly modified when it was utilized 
in a study by Ferri et al., to include half-point intervals (0 – 3.5), allowing for better 
statistical analysis of the data.28 
Overall, several studies have shown to some degree that treatment with exogenous 
melatonin can bring about a reduction in the potentially dangerous symptoms associated 
with RBD. Melatonin also seems to be associated with a very low risk of side effects. 
While evidence thus far has shown clonazepam to be equally efficacious in reducing 
RBD symptoms, this therapy comes with a much higher side effect burden. These side 
effects tend to be even more pronounced in patients who have neurological disorders 
such as Parkinson’s disease. To this date, however, no randomized placebo-controlled 
trials have directly compared melatonin to a placebo in terms of efficacy in decreasing 
RBD symptoms. Furthermore, no studies have analyzed this treatment use specifically in 
a population of Parkinson’s patients.25    
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METHODS 
 
Study design 
The proposed study will be a double-blind, placebo-controlled randomized clinical trial 
comparing two treatment arms, melatonin and a placebo.  
Study population and sampling 
The population to be studied in this trial are patients with diagnosed Parkinson’s disease, 
specifically early-moderate disease (stage III or lower on Modified Hoehn and Yahr 
scale16). Selection criteria will also include a formal diagnosis of RBD based on 
International Classification of Sleep Disorders diagnostic criteria.22 Patients will be 
excluded if they have any poorly controlled comorbid medical conditions that affect sleep 
(such as OSA requiring nighttime ventilation assistance), or are prescribed any 
medications that have an effect on sleep, such as benzodiazepines, anti-psychotics, and 
antidepressants. Patient’s may remain on a standard PD medication regimen and will be 
instructed that this regimen may not be changed while they remain involved in the study. 
No exclusions will be made based on patient demographics (age, gender, ethnicity, etc.) 
An appropriate sample size of at least 52 patients will be selected in order to achieve an 
alpha value of 0.05, a beta value of 0.2, and to bring about an estimated mean clinical 
decrease of at least 0.5 on the REM Behavior Disorder Severity Scale (RBDSS). These 
parameters were determined using a baseline mean RBDSS score of 2.1, based on 
analysis of the tool by Sixel-Döring et al.27, and an estimated mean RBDSS score of 1.6 
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following treatment.  Sample size was determined using an online sample size 
calculator.29  
Treatment (or intervention) 
The intervention performed in this study will be initiation of a treatment of melatonin or a 
placebo. Subjects assigned to the melatonin treatment arm will be given Melatonin 
Quick-Sorb (Great Earth, Los Angeles, CA, U.S.A), as was used in the initial melatonin 
study by Kunz and Bes.26 The dose of melatonin administered will be 6mg, as this was 
the median effective dose determined by McCarter et al.25  Subjects will be randomly and 
blindly assigned to a medication, and instructed to take the assigned medication for a 
period of six weeks. During the treatment month, subjects will be instructed to take the 
assigned medication each night, approximately 30-60 minutes before they plan to sleep. 
Subjects will also be asked to maintain a fairly consistent bedtime during their time in the 
study, to promote circadian rhythm regulation.  
Study variables and measures 
The independent variable of this study is the initiation of a medication intervention with 
either melatonin or a placebo. The dependent variable to be analyzed will be the subject’s 
score on the REM Behavior Disorder Severity Scale (RBDSS) during polysomnographic 
study. The study will utilize the modified RBDSS scale as was used by Ferri et al. which 
will evaluate subjects on a 0 – 3.5 scale.28 Comparison will be made between the 
patient’s baseline RBDSS score and their score following six weeks of treatment. The 
primary end point of the study is to determine if there is a significant change in the 
 24 
patients RBDSS score following a medication intervention, compared to the subject’s 
baseline.  
Recruitment 
Subjects will be referred to the study by movement disorder specialists at Boston Medical 
Center. Patients who will be referred will have an existing diagnosis of Parkinson’s 
disease, who also report sleep dysfunction, not currently being controlled with 
medications. Subjects will then be seen by a clinician involved in the study to ensure they 
meet clinical criteria for the trial.  
Data collection 
Subjects who agree to take part in the study will be asked to take part in an initial PSG 
study in order to formally diagnose RBD, and also to obtain a baseline analysis of their 
RBD symptom severity on the RBDSS. Following the initial PSG, subjects who meet 
criteria for the study will begin their assigned medication protocol for a six week period, 
and will then report for a follow-up PSG. PSG will take place in a standard sleep lab, and 
will follow a protocol used by Kunz and Bes in their study of RBD patients.26 Subjects 
will be in a noise-controlled environment with lights out from approximately 22:00 to 
06:00. Subjects will be analyzed with EEG for sleep staging, EMG (submentalis, and left 
and right tibialis), EKG, and oral and nasal air flow thermistor to measure sleep 
respiratory patterns. The entire study will take place under video surveillance to be 
analyzed by a trained technician, who will score the subjects according to the RBDSS.  
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Data analysis 
After baseline and post-treatment RBDSS scores are determined for each subject, the 
difference will be computed in order to determine the change in each patient’s symptom 
severity following the assigned treatment regimen. Data will be grouped according to 
subject’s age, and PD severity (Hoehn and Yahr scale), as these variables can have an 
impact on patient’s REM sleep quality. Mean and standard deviation will be calculated 
for both treatment groups. The melatonin and placebo group data will be compared to one 
another by Student’s T test. Variation amongst subjects within each group will be 
analyzed via ANOVA.   
Timeline and resources 
Allowing for time to plan, allocate resources, recruit patients, and receive proper 
approval from the IRB, the study could reasonably begin in January 2017. All subjects 
will require two PSG studies with a six week interim between studies. As PSG resources 
will most likely be limited, not all patients will be able to start and end the study at the 
same time. Therefore, a completion date around April 2017 would be appropriate to 
anticipate.  
 In terms of human resources that will be necessary, there will be one primary 
investigator in charge of project oversight. Two to three clinicians will be required for 
clinical evaluation of potential subjects to ensure they meet criteria for the study. One or 
two PSG technicians will be needed to oversee the PSG studies, as well as two 
individuals trained to evaluate PSGs, specifically trained in RBDSS protocol. One 
statistician will likely be useful as well, to assist with data analysis.  
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 For materials, all that will be necessary are the PSG labs containing all necessary 
equipment for conducting the sleep studies.  
Institutional Review Board 
In order to perform research on human subjects, an application for full-board approval of 
the Institutional Review Board of Boston University Medical Center will be submitted. 
Approval from the IRB will be obtained prior to the start of patient recruitment.  
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CONCLUSION 
Discussion 
While the proposed study is unique in many ways, and will provide helpful insight that 
may guide future management of RBD in Parkinson’s patients, there are several 
weaknesses to the study design that must be considered. For one, limitations exist in the 
use of PSG sleep analysis. Patients will likely not sleep as well during a sleep study as 
they would in the comfort of their own homes, especially with the added discomfort of all 
the measurement tools attached to them as they sleep. Even at baseline, RBD patients will 
likely have great variation in their behaviors during a sleep study, so this method of 
analysis may prove to be a difficult tool for this study. An additional limitation to this 
trial is the RBDSS scale. Even using the modified RBDSS, the scale is quite limited, only 
allowing a rating from 0 – 3.5, hardly accounting for the vast array of behaviors that 
patients could present. 
 As far as generalizability of the study, the goal is that the population recruited will 
make the results highly generalizable to all PD patients with RBD. Patients at Boston 
Medical Center represent a highly diverse patient population, which works in favor of 
generalizing the data. Regardless of what insight the data provides, however, clinicians 
must understand that sleep is a very complex physiologic process, and it is impossible to 
predict how any individual patient will react to a medical intervention, especially when a 
comorbid neurodegenerative process is at play.  
 Despite the aforementioned shortcomings of this study, there are several strengths 
that set this trial apart from any that have been previously performed. For one, this trial 
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plans to provide randomized clinical trial evidence of a benefit of using melatonin in a 
subset of patients with RBD. No previous studies in RBD patients thus far have examined 
melatonin vs. placebo in a randomized clinical trial format. Furthermore, this trial is 
using objective data from a PSG sleep analysis. Most studies of RBD management thus 
far have used subjective data, such as a survey sent to patients, which comes with a 
significant level of recall bias and other potential distortion to the data. One of the 
greatest benefits this study will provide, however, is data specifically geared toward RBD 
patients with concurrent Parkinson’s disease. No studies to date have specifically looked 
at RBD treatments in this specific subset of patients.  
Summary 
RBD is a potentially dangerous and frightening disorder that affects over 60% of 
individuals with PD. Currently, the standard of care for managing these symptoms is with 
clonazepam. This medication can cause several detrimental side effects, especially in the 
PD patient population, including daytime somnolence, worsening cognitive function, and 
impaired physical coordination. Overall, several small case studies have shown a 
potential benefit from the use of melatonin for management of the symptoms of RBD. 
The efficacy of melatonin in managing RBD symptoms seems to be at least comparable, 
if not greater, than that of the current standard of care, clonazepam. However, this has not 
yet been shown in a randomized clinical trial.  
 If the hypothesis proves correct, then the proposed study will provide evidence 
that melatonin is an efficacious treatment option for RBD in PD patients. Further studies 
will need to be pursued in the future, however, to determine how melatonin directly 
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compares to clonazepam in its efficacy and side effect burden in treating RBD. 
Additional studies will also have to be performed to determine the efficacy of melatonin 
for managing RBD in patients without PD, as this study is specifically focused on only 
the PD patient population.  
Clinical and/or public health significance 
As the population in our country becomes more advanced in age, diseases such as PD are 
going to continue to increase in prevalence. Modern medical advances have allowed PD 
patients to live longer than ever before, but with longer lifespan comes other risks that 
need to be properly managed. With as many as two-thirds of PD patients facing sleep 
dysfunction and RBD symptoms, finding an effective way of managing these patients is a 
significant clinical problem that needs to be addressed.  
 A diagnosis of PD not only puts patients at increased risk of RBD, but also puts 
them at greater risk for being negatively impacted by treatment with clonazepam. By 
studying a population of PD patients for this study, ideally melatonin as a treatment 
alternative to clonazepam will prove efficacious for these individuals. This will 
drastically improve quality of life in these patients, allowing them to have more energy 
during wakeful hours, less cognitive impairment, and no further deterioration of their 
physical coordination. This simple medication change could help PD patients to be safer 
in their homes, potentially allowing them to continue living independently for a longer 
duration of time. Ideally, melatonin treatment will prove to be efficacious in this 
population to allow for an additional treatment option available for clinicians to consider.  
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